Investment Thesis
Annovis Bio is a pre-revenue pharmaceutical company with severe cash burn of $25.6M annually, consuming its cash reserves at an unsustainable rate. With $19.5M in cash and negative $25.6M operating cash flow, the company has less than one year of cash runway remaining. The absence of any revenue generation combined with massive operating losses and deteriorating financial position presents existential risks.
ANVS Strengths
- Strong liquidity position with $19.5M in cash relative to $21.1M total assets
- Minimal debt burden with 0.00x debt-to-equity ratio reducing financial leverage risk
- Current ratio of 2.15x indicates ability to meet short-term obligations
ANVS Risks
- Zero revenue with no path to profitability visible in near term
- Negative operating cash flow of $25.6M annually indicating unsustainable burn rate with <1 year cash runway
- Pre-clinical stage pharmaceutical company dependent on successful drug development, regulatory approval, and commercialization
- Severe negative profitability metrics: -171.2% ROE, -136.9% ROA, -28.9M net loss
- No insider buying activity in last 90 days suggesting lack of management confidence
Key Metrics to Watch
- Quarterly operating cash flow trend and remaining cash balance
- Clinical trial progress and regulatory milestones for pipeline assets
- Burn rate sustainability and capital raise requirements
ANVS Financial Metrics
ANVS Profitability Ratios
ANVS Balance Sheet & Liquidity
ANVS 5-Year Financial Trend
5-Year Trend Summary: Annovis Bio, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.31 indicates the company is currently unprofitable.
ANVS Growth Metrics (YoY)
ANVS Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$1.1M | $-0.37 |
| Q2 2025 | N/A | -$1.1M | $-0.32 |
| Q1 2025 | N/A | -$1.1M | $-0.32 |
| Q3 2024 | N/A | -$1.1M | $-0.97 |
| Q2 2024 | N/A | -$1.1M | $-0.44 |
| Q1 2024 | N/A | -$1.1M | $-0.72 |
| Q3 2023 | N/A | -$5.2M | $-0.79 |
| Q2 2023 | N/A | -$5.2M | $-0.73 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ANVS Capital Allocation
ANVS SEC Filings
Access official SEC EDGAR filings for Annovis Bio, Inc. (CIK: 0001477845)